comparemela.com

Latest Breaking News On - Liso cel - Page 3 : comparemela.com

Dr Nastoupil on the Use of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

Pirtobrutinib, Liso-Cel Could Expand Treatment Arsenal for Relapsed/Refractory CLL

Mazyar Shadman, MD, MPH, discusses the evolution of BTK inhibitors in CLL, highlights how treatment patterns have evolved with the continued emergence of data on ibrutinib, acalabrutinib, and zanubrutinib, and expands on how pirtobrutinib and liso-cel could address unmet needs for this patient population.

TRANSCEND FL: Phase 2 Study Results of Lisocabtagene Maraleucel in Patients With R/R Follicular Lymphoma

Liso-cel Earns European Approval for Relapsed/Refractory LBCL After 1 Prior Therapy

The European Commission has approved lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.